Literature DB >> 17654516

Exposure of normal human melanocytes to a tumor promoting phorbol ester reverses growth suppression by transforming growth factor beta.

Melanthia Stavroulaki1, Dimitris Kardassis, Ekaterini Chatzaki, George Sakellaris, Carsten Lindschau, Hermann Haller, Androniki Tosca, Konstantin Krasagakis.   

Abstract

Transforming growth factor-beta (TGF-beta), a potent inhibitor of normal melanocyte growth, does not significantly suppress growth of melanoma cells. The mechanism of melanocyte desensitization to TGF-beta in the transformation process remains largerly unknown. We investigated whether the tumor promoting phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) may induce melanocyte resistance to TGF-beta. Cell proliferation and DNA synthesis of normal human melanocytes were strongly inhibited by TGF-beta, whereas in the presence of TPA remained largerly unaffected. The inactive phorbol ester 4alpha-phorbol 12,13 didecanoate did not modify the TGF-beta antiproliferative effect, whereas the diacylglycerol analog 1-oleoyl-2-acetyl-sn-glycerol counteracted TGF-beta effects. Protein kinase C (PKC) is the major cellular receptor of tumor promoting phorbol esters. PKC-alpha expression and phosphorylation were almost completely downregulated under combined treatment with TGF-beta + TPA at 24 and 72 h, as shown by immunoblots. Confocal microscopy demonstrated that TGF-beta-induced nuclear accumulation of PKC-alpha was abolished in the presence of TPA at the same time points. The selective PKC inhibitor Ro-31-8220 weakened the TGF-beta antiproliferative effect. Smads are central mediators for TGF-beta signal transduction. Smad-dependent transcriptional activity was suppressed in TGF-beta-treated melanocytes in the presence of TPA, as well as in ALK5 (constitutively active type I TGF-beta receptor)- or Smad3 + Smad4-transfected melanocytes in the presence of Ro-31-8220. In addition, an antisense oligodeoxynucleotide against PKC-alpha abolished TGF-beta-driven Smad-mediated transcription. These findings show that tumor promoting phorbol esters induce melanocyte resistance to TGF-beta, associated with downregulation of PKC-alpha and suppression of Smad-dependent transcription. This may represent an important mechanism for expansion of melanocytes exposed to PKC-targeting tumor promoters. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17654516     DOI: 10.1002/jcp.21207

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  5 in total

1.  Insights into the Role of PAX-3 in the Development of Melanocytes and Melanoma.

Authors:  Jessica Diann Hathaway; Azizul Haque
Journal:  Open Cancer J       Date:  2011-01-01

Review 2.  Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place?

Authors:  Ahmed Lasfar; Karine A Cohen-Solal
Journal:  Carcinogenesis       Date:  2010-07-23       Impact factor: 4.944

3.  Nestin expression is upregulated in the fibrotic rat heart and is localized in collagen-expressing mesenchymal cells and interstitial CD31(+)- cells.

Authors:  Vanessa Hertig; Kim Tardif; Marc Andre Meus; Natacha Duquette; Louis Villeneuve; Fanny Toussaint; Jonathan Ledoux; Angelino Calderone
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

4.  BRAFV600E induces reversible mitotic arrest in human melanocytes via microrna-mediated suppression of AURKB.

Authors:  Andrew S McNeal; Rachel L Belote; Hanlin Zeng; Marcus Urquijo; Kendra Barker; Rodrigo Torres; Meghan Curtin; A Hunter Shain; Robert Hi Andtbacka; Sheri Holmen; David H Lum; Timothy H McCalmont; Matt W VanBrocklin; Douglas Grossman; Maria L Wei; Ursula E Lang; Robert L Judson-Torres
Journal:  Elife       Date:  2021-11-23       Impact factor: 8.140

5.  DNA polymerase ζ deficiency causes impaired wound healing and stress-induced skin pigmentation.

Authors:  Sabine S Lange; Sarita Bhetawal; Shelley Reh; Katherine Leslie Powell; Donna F Kusewitt; Richard D Wood
Journal:  Life Sci Alliance       Date:  2018-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.